Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4369)
All Articles published online
|
Publishing Process of This Article
|
Jul 28, 2025 (publication date) through Apr 29, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Ma L, Zhang MH, Xu YF, Hao YX, Niu XX, Li Y, Xing HC. Fecal microbiota transplantation: A promising treatment strategy for chronic liver disease. World J Gastroenterol 2025; 31(28): 105089 [PMID: 40741477 DOI: 10.3748/wjg.v31.i28.105089] |
|
|
|
| All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply. | |
| For: | Ma L, Zhang MH, Xu YF, Hao YX, Niu XX, Li Y, Xing HC. Fecal microbiota transplantation: A promising treatment strategy for chronic liver disease. World J Gastroenterol 2025; 31(28): 105089 [PMID: 40741477 DOI: 10.3748/wjg.v31.i28.105089] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v31/i28/105089.htm |
| Number | Citing Articles |
| 1 |
Irene Díaz-Alberola, Daniel E. Di Zeo-Sánchez, Vanesa Garrido-Rodríguez, Carlos López-Gómez, Cristina Rodríguez-Díaz, Raul J. Andrade, M. Isabel Lucena, Marina Villanueva-Paz, Eduardo García-Fuentes. The gut–liver axis in drug-induced liver injury (DILI): Interplay between gut microbiota, intestinal barrier, and immune system. Acta Pharmaceutica Sinica B 2026; doi: 10.1016/j.apsb.2026.04.014
|
| 2 |
Man Sun, Dan Zang, Jun Chen. Cross-platform assessment of short-form video quality on the gut–liver axis: informational integrity and engagement disparity. Frontiers in Cellular and Infection Microbiology 2025; 15 doi: 10.3389/fcimb.2025.1732375
|
| 3 |
Ameen S. S. Alwashmi, Najeeb Ullah Khan, Ahsanullah Unar. Decoding Microbiota–Immune Interplay in Viral Pathogenesis: Toward Next-Generation Antiviral Therapies. Probiotics and Antimicrobial Proteins 2026; doi: 10.1007/s12602-026-10999-8
|
| 4 |
Ilaria Cosimato, Annalisa Brescia, Gianluigi Franci, Vincenzo Casolaro, Veronica Folliero. Emerging Therapeutic Approaches for Modulating the Intestinal Microbiota. Pharmaceutics 2026; 18(2): 197 doi: 10.3390/pharmaceutics18020197
|
| 5 |
Xianting Liang, Junning He, Qiuting Wu, Lixiang Fu, Yongfang Liu. Gut microbiome in alcohol-associated liver disease: interactions and therapeutic strategies. Frontiers in Pharmacology 2026; 17 doi: 10.3389/fphar.2026.1770833
|
| 6 |
Yaqi Li, Yiping Xin, Wenlu Zong, Xiaoyu Li. The role of oral microbiota in digestive system diseases: current advances and perspectives. Journal of Oral Microbiology 2025; 17(1) doi: 10.1080/20002297.2025.2566403
|
| 7 |
Yanan Duan, Mengting Yang, Miaomiao Li, Yu Sun, Shiguo Liu. Microbiome and metabolite signatures for cirrhosis to HCC risk stratification: progress, controversies, and gaps. Frontiers in Cellular and Infection Microbiology 2026; 16 doi: 10.3389/fcimb.2026.1793213
|